The emergence of gene inactivation by homologous recombination methodology in embryonic stem cells has revolutionized the field of mouse genetics. Indeed, the availability of a rapidly growing number of mouse null mutants has represented an invaluable source of knowledge on mammalian development, cellular biology and physiology and has provided many models for human inherited diseases. In recent years, improvements of the original 'knock-out' strategy, as well as the exploitation of exogenous enzymatic systems that are active in the recombination process, have considerably extended the range of genetic manipulations that can be produced. For example, it is now possible to create a mouse bearing a targeted point mutation as the unique change in its entire genome therefore allowing very fine dissection of gene function in vivo. Chromosome alterations such as large deletions, inversions or translocations can also be designed and will facilitate the global functional analysis of the mouse genome. This will extend the possibilities of creating models of human pathologies that frequently originate from various chromosomal disorders. Finally, the advent of methods allowing conditional gene targeting will open the way for the analysis of the consequence of a particular mutation in a defined organ and at a specific time during the life of a mouse.
Introduction
Over the last few last decades, the mouse has become the animal model of choice for study of the various aspects of mammalian development and physiology (Paigen, 1995) . Apart from being the easiest and cheapest laboratory mammal to maintain, the availability of mouse genetic resources and the more recent ability to genetically manipulate the mouse genome have contributed to making it a powerful resource for the study of most biological systems. At the end of the 1980s, a major breakthrough in mouse molecular genetics emerged from the convergence of two research fields: on the one hand, the development of techniques for the screening and the isolation of rare homologous recombination events in mammalian cells (Doetschman et al., 1987; Thomas and Capecchi, 1987) and, on the other hand, the development of embryonic stem (ES) cell technology (Robertson, 1987) . ES cells are derived from the inner cell mass of a mouse blastocyst and retain their totipotency when cultured and subjected to genetic modification. When transferred into an early mouse embryo, they can participate in the generation of all cell lineages including germ cells, thereby transmitting their genotype to the next generation. The convergence between these two techniques made the targeted mutagenesis in mice of any cloned gene or locus feasible. Since the first reports (Koller and Smithies, 1989; Zijlstra et al., 1989) , an exponentially growing number of mutant mice has been produced using this technology (327 compiled by Brandon et al., 1995;  more than 800 reported in T-Base http://www.jax.ozg/cbase). Analysis of the phenotypes of these mutants, the vast majority of which harbour null mutations, has brought new insights into gene function (Capecchi, 1989; Bronson and Smithies, 1994) and led to the creation of several mouse models of human genetic disease (Smithies, 1993; Smithies and Maeda, 1995) . More recently, crosses between mice harbouring null mutations in different genes has allowed the refinement of gene hierarchies and interactions (Horan et al., 1995; Rudnicki and Jaenisch, 1995) . However, deciphering gene function may not only benefit from loss of function analysis, but may also require the creation and the characterization of more sophisticated perturbations such as subtle mutations, lineage-specific and inducible mutations and large-scale genome alterations. The aim of this article is to review the different systems that have recently been established which considerably extend the range of genetic manipulations that can be produced in mice. First, we focus on methods which are based on the refinement of selection procedures originally used to generate 'knock-out' (KO) mice. Second, approaches which involve the use of enzymatic systems from lower organisms are considered.
Improvement of classical gene targeting: from null mutations to other types of genomic modifications
Originally, gene targeting in mice involved generating null mutations by the introduction of a selectable marker gene into the gene of interest. The marker served simultaneously as a mutagen. In recent years, however, researchers have extended this methodology towards the creation of other types of mutations (point mutations, small deletions, insertions etc.) or even chromosomal alterations.
Subtle mutations
Subtle alterations of the genome such as point mutations, small deletions or insertions cannot be generated via classical gene targeting technology. The presence of the selectable marker gene with its own promoter and strong ubiquitous regulatory sequences in the modified allele is not neutral and could have unforeseen consequences on the expression of the target gene and/or neighbouring genes (see Pham et al., 1996 and references therein) . In order to generate a locus harbouring a subtle modification but devoid of exogenous sequences, several groups have tried to co-transform cells with a replacement construct and a selectable marker on separate DNA fragments. However, only a very low proportion of cells underwent a gene targeting event together with random integration of the selectable marker, therefore making this approach unsuitable. Since then, two main strategies have been developed and are described below. An alternative approach based on the use of a site-specific recombinase is discussed in a separate section.
Insertion and intrachromosmal recombination
The first strategy was called 'hit and run' and 'in and out' by different groups (Hasty et al., 1991; Valancius and Smithies, 1991) . The technique involves the insertion of a targeting vector and its subsequent excision together with the selectable marker gene. Targeting constructs used for this technique are composed of genomic DNA containing the desired modification, flanked by both positive (neomycin resistance gene, neo) and negative (herpes simplex virus thymidine kinase gene, hsv-tk) selectable marker genes. When linearized in the region of homology the construct is prone to an insertional recombination event generating a partial duplication of the locus separated by the plasmid backbone and the two selectable markers (Figure 1a ). Subsequent counter-selection of the correctly targeted clones in the presence of ganciclovir (a non-toxic nucleotid analogue which is metabolized to a toxic one by the hsv-tk enzyme) allows the recovery of rare revertants which have lost the hsv-tk marker gene. Such revertants resolve the partial duplication by a single reciprocal intrachromosomal recombination event, leading to the excision of the duplicated sequences and selection cassettes, thereby creating the desired modified allele (Figure 1b ). This technique has been successfully employed to generate various mutated ES cell lines and mutant mice (Valancius and Smithies, 1991; Ramirez-Solis et al., 1993; Wu et al., 1994; Horan et al., 1995; Horie et al., 1995; van Doorninck et al., 1995; MacMillan et al., 1996; Toth et al., 1996; Takaesu et al., 1997) . However, the method has several drawbacks. First, depending on the site of the intrachromosomal recombination, the modification can reside in the part which is excised during the second step. In this case, a wild-type allele is re-created and this could account for up to 95% of ganciclovir-resistant clones (see for example van Doorninck et al., 1995) . Second, the success of the experiment relies on the rate of intrachromosomal recombination, and variation of 1000-fold in this rate between two loci has been reported (Hasty et al., 1991) . Therefore, the intrachromosomal recombination rate could be limiting for an Figure 1 . Introduction of a point mutation using the 'hit and run' strategy. (a) The targeting construct contains the region of homology to the target gene containing the point mutation (*) in one of the exons (grey shaded boxes). The two selectable marker genes are located outside the region of homology. Positive selection allows screening for homologous recombinants (G418 R ) between the targeting construct linearized in the region of homology and the target locus (black shaded boxes) leading to partial duplication of the locus. (b) An intrachromosomal recombination event in the targeted allele subsequently leaves the locus harbouring a point mutation and devoid of exogenous sequences. Negative selection is used to select for this event.
efficient excision step at some loci. A final drawback of this approach is that the alteration has to be present in the targeting construct at the onset of the experiment. Consequently, introduction of another mutation necessitates a novel complete two-step experiment. Together, these limitations could explain the relatively small amount of successful targeting using this technique since the initial report. Double replacement gene targeting This strategy has been called 'double replacement' or 'tag and exchange' by different groups (Askew et al., 1993; Stacey et al., 1994; Wu et al., 1994) . The first step involves a replacement recombination event allowing the introduction of both positive and negative selectable marker genes at the locus. During a second replacement gene targeting event, the selectable markers are exchanged for a mutated version of the locus and enrichment for such an event is achieved using the negative selection. As for the previous strategy, a combination of both positive (neo) and negative (hsv-tk) selectable marker genes may be used. However, Stacey et al. (1994) have developed a strategy based on the use of only one selectable marker. This peculiar selectable marker gene is the hypoxanthine-guanine-phosphoribosyl transferase (hprt) gene which can be selected for [hypoxanthine, aminopterin, thymidine, (HAT) medium] as well as against [6 thioguanine (6-TG) medium]. This scheme is illustrated in Figure 2 . In a first step, an hprt minigene containing replacement construct is introduced into an hprt -male ES cell line, harbouring an inactivated endogenous hprt gene on its X chromosome. Correctly targeted ES clones are then identified among the Figure 2 . Introduction of a point mutation using the double replacement strategy. This method makes use of embryonic stem (ES) cells bearing a null mutation in the endogenous hprt gene. If, instead of the hprt cassette, both positive and negative selectable markers are employed, a wild-type ES cell line could be used. (a) In the first step, an hprt cassette is introduced into the target locus by homologous recombination. The resulting ES clones are hprt ϩ and are selected in hypoxanthine, aminopterin, thymidine (HAT) medium (b). This cassette can then be exchanged for a mutated version of the targeted locus. The targeted cells revert to an hprtphenotype and can therefore be selected for in the presence of 6-thioguanine (6-TG).
HAT resistant clones (Figure 2a) . In a second step, a second replacement construct harbouring a specific mutation and no selectable gene is introduced into the modified ES cells. Clones with the desired modification are identified among the 6-TG resistant clones (Figure 2b ).
This technique has been applied to several loci (Askew et al., 1993; Gondo et al., 1994; Stacey et al., 1994; Wu et al., 1994; Melton et al., 1997; Whyatt and Rathjen, 1997) . Its main advantage is that several subtle mutations at the same locus can be generated. The initial targeted cell line can serve as a substrate for replacement by various constructs harbouring different modifications in the surrounding genomic region. This method has been recently illustrated by Moore et al. (1995 Moore et al. ( , 1998 with the prion protein gene (Prnp). In a first step, a Prnp null allele was created by replacing the third exon of this gene by an hprt minigene. Subsequently, this initial cell line was used to derive a series of five different alleles containing different amino acid substitutions. The analysis of the effect of these mutations showed that mouse scrapie incubation time is controlled by the nature of the codon present at position 108 and/or 189 of the prion protein. This demonstrated that the Sinc/Prni locus, previously identified as the major gene controlling incubation time, is congruent with the Prnp gene (Moore et al., 1998) . The main difficulty of this technique is that in some instances recovery of targeted clones may be compromised by a high background of nontargeted clones which survive selection due to the loss of the hprt cassette expression. This may result from spontaneous physical loss of the cassette or from the repression of minigene expression by local position effects. An example of the latter was recently described by Melton et al. (1997) . Therefore, a new hprt-expressing cassette which showed more consistent expression was devised; use of this novel construct noticeably reduced the background level (Melton et al., 1997) . However, the new cassette was double in size (ranging from 2.7 to 5.7 kb), rendering it less versatile for the making of the first replacement construct.
'Knock-in'
A variation of the standard knock-out method consists of the introduction of a foreign gene into a target locus, or 'knockin'. Using such an approach, one can place any gene of interest (e.g. oncogene, reporter gene, etc.) under the control of the cis-acting regulatory elements of another gene, a situation which had been achieved up until now only by classical transgenesis. But this approach presents considerable advantages which obviate the serious limitations imposed by standard transgenic technology. First, homologous recombination places the transgene in the context of the complete set of cis-acting regulatory elements that normally control the expression of the endogenous gene. Second, the targeted transgene is no longer subject to position effects as a result of random integration sites (see Wilson et al., 1990) . The most common application of this technology involves the targeting of lacZ reporter gene into various loci (see for example Le Mouellic et al., 1990; Colucci-Guyon et al., 1994) . This has been of great help in accurately defining the expression pattern of certain genes and, in some instances, in revealing previously unknown sites of expression (Tajbakhsh and Buckingham, 1995) . Furthermore, this approach is invaluable for visualizing the fate of mutated cells in the case of embryonic lethal mutations (see for example Schneider-Maunoury et al., 1993; Tajbakhsh et al., 1996) .
Most importantly, this approach has proved to be a powerful tool in studying the functional relationship between members of a gene family and their potential ability to functionally compensate for each other (Cooke et al., 1997) . For example, Wang et al. (1996) have removed the muscle-specific transcription factor myf5 gene and replaced it by another member of the myogenic basic helix-loop-helix (bHLH) family, myogenin. Both transcription factors share a similar DNA binding domain and can convert fibroblasts into muscle cells in vitro. Their transcriptional activation domains, however, are different and they exhibit different temporal expression patterns. Strikingly, whereas the myf5 knock-out mice died at birth because of a rib cage defect, the myf5-myogenin knock-in mice have normal rib cages and are viable and fertile. Therefore, this demonstrates that myogenin can compensate for myf5 at least for rib cage formation. Using a similar approach, Hanks et al. (1995) showed that despite the fact that mutations in En-1 or En-2 genes lead to contrasting phenotypes, they nevertheless share similar biological functions. Taken together, these results suggest that functional differences between two genes coding for similar products could depend at least partly on differences in their temporal and spatial expression patterns.
Deletions
Recently You et al. (1997) used the general selection procedures described above for the generation of numerous deletions in a defined chromosomal region. This modified approach involves targeting by homologous recombination a negative selectable marker (hsv-tk) into a given gene, irradiation of correctly targeted clones followed by selection of hsv-tk -clones. Finally, the extent of the various deletions obtained is defined through the analysis of polymorphic markers (the ES cells used are derived from F 1 hybrid mice) (Figure 3) . In their study, You et al. (1997) used a gene in the T (brachyury) region of chromosome 17 for targeting of the hsv-tk cassette by homologous recombination. They recovered and defined several ES cell clones bearing deletions of various lengths, most of which retained the ability to colonize the germ line. In principle, this strategy could be applied to any region of the mouse genome and therefore extends the scope of complementation analysis such as the deletions obtained by classical mutagenesis at the albino locus (Holdener-Kenny et al., 1992) .
Use of exogenous enzymatic systems to refine genome manipulation
In the experiments described above, the modification of the target locus, governed by the design of the targeting vectors and the various selection schemes, is mediated by the ES cells' endogenous recombination machinery. Recently, several wellcharacterized enzymatic systems discovered in other organisms and active in the recombination process have been shown to work efficiently when transferred into mammalian cells (Kilby et al., 1993; Choulika et al., 1994; Jasin, 1996) . The contribution of such systems to gene targeting is described in this section.
The Cre-Lox P system
Site-specific recombinases are enzymes which promote recombination via recognition of specific short nucleotide sequences without any added factor (Kilby et al., 1993) . Two such recombinases have been investigated: one from the bacteriophage P1, called Cre recombinase which recognizes Lox P sites; the other from Saccharomyces cerevisiae called Flp recombinase which recognizes FRT sites. Both Lox P and FRT sites are 34 bp long and asymmetrical. Depending on the relative orientation of the recognition sites (Lox P or FRT) the recombinases may catalyse excision (same orientation) or inversion (opposite orientation) of the DNA segments lying between these sites. In addition, the reaction is reversible and can therefore be employed to introduce a circular molecule containing one recombination site (Lox P or FRT) into a desired sequence which already contains one such site (Logie and Stewart, 1995; Araki et al., 1997) . Both recombinases have been shown to work efficiently in mammalian cells, and, of particular interest, in ES cells (Sauer and Henderson, 1988; Dymecki, 1996) . However, we will detail only the Cre-Lox P system which has been used more extensively (readers interested in the Flp-FRT system are referred to Dymecki, 1996 and references therein) . 'Clean' and subtle mutations The first application of the Cre-Lox P system is to create 'clean' (i.e. devoid of selectable markers) and subtle mutations. To this end, a targeting vector is constructed bearing the desired mutation in the gene of interest and the selectable marker in an intron, flanked by two Lox P sites in the same orientation ('floxed' sequence). ES cells targeted in the endogenous gene are then identified and transfected with a Cre expressing vector which promotes the excision of the selectable marker: this results in ES cells bearing the desired mutation in the gene of interest, with the presence of only one Lox P site as foreign sequence (Figure 4 ). To avoid a putative interference of this Lox P site with the function of the target gene, it should be placed away from any known regulatory element. This strategy has been used to create 'clean' mutations in various immunoglobulin genes and no evidence of an effect of the remaining 34 bp Lox P site was observed (Ferradini et al., 1996; Pelanda et al., 1996; Torres et al., 1996; Xu and Baltimore, 1996) . An alternative and more direct means of obtaining mice bearing the 'clean' mutation is to generate germline chimeras with the recombinant ES cells bearing the floxed selectable marker. A male chimera is then crossed with Figure 5 . Creation of defined deletion/translocation using the CreLox P system. (a) A first targeting event introduces a Lox P site (triangle) and a partial non-functional selectable gene (hyg) at a first locus. The neo cassette is used as a first positive selectable marker. (b) The targeted cell is then subjected to a second homologous recombination event leading to the introduction of a second Lox P site and the complementary region of the nonfunctional selectable gene (ro) at a second locus. The puromycin cassette (puro) serves as a second positive selectable marker. (c) Transient expression of the Cre recombinase in the double targeted cell results in the restoration of a functional hygro selectable marker gene. When the two targeted loci are on the same chromosome, the action of the Cre recombinase leads to a deletion between the two Lox P sites; when they are on two separate chromosomes, it leads to a translocation. a transgenic female expressing the Cre recombinase during early development. The resulting progeny will harbour the 'clean' mutated allele in almost all their cells and will transmit the mutation to the next generation. Several studies, using different promoters to govern Cre expression, have demonstrated the efficiency of this approach (see for example: Schwenk et al., 1995; Lakso et al., 1996; Lewandoski et al., 1997) . Large chromosomal modifications An extension of the Cre-Lox P system is to try to create chromosomal rearrangements including deletions encompassing long distances or translocations which involve the recombinases acting in trans. To achieve this goal particular selection strategies should be used because the recombinase is less efficient over long distances or when acting in trans. Thus, two Lox P sites are first introduced in chosen positions and in the suitable orientation by two successive steps of homologous recombination ( Figure 5a and b) ; the Lox P sequences are each flanked by a half of the selectable gene arranged in such a way that after transient expression of Cre in the double targeted cells, the recombination event creates an active selectable gene (Figure 5c ). Such a strategy has been successfully used to generate ES cells bearing a translocation between chromosome 12 and chromosome 15 at the sites of immunoglobulin heavy chain and c-myc genes respectively (Smith et al., 1995) . Similarly, deletions (and also inversions or duplications) as large as 3-4 centiMorgans, have also been created in ES cells, and mice bearing the engineered chromosomes have been generated (Ramirez-Solis et al., 1995) . More specifically, a similar approach was undertaken to produce ES cells and mice bearing a 200 kb deletion encompassing most of the amyloid precursor protein APP gene (Li et al., 1996) .
The Cre-Lox P system and conditional gene targeting The use of ES cells and homologous recombination to introduce mutations into a given gene has been extremely useful in the study of gene function. However, this approach has some limitations: first, a mutation which induces lethality at a given stage of embryonic development precludes the study of gene function later in development; second, when a gene has a tissue-or organ-specific expression pattern, analysis of its function, based on the effects of a mutation present in the germ line and therefore potentially expressed in all the cells of the organism, might be complicated. Several recent studies indicate that these limitations may be overcome through the use of the Cre-Lox P system, which enables conditional targeting, namely the expression of a mutation at a given time and/or in a given type of cell or tissue (Torres and Kühn, 1997 and references therein).
The strategy for conditional gene targeting using the CreLox P system involves two types of transgenic mouse lines: the first bears the target gene (or gene segment) flanked by two Lox P sites in the same orientation and positioned in such a way that it does not prevent normal gene activity ('floxed' gene); the second line contains a fusion transgene expressing Cre recombinase. When these two mouse lines are crossed, depending on the regulatory sequences present in the fusion transgene, the floxed gene will be deleted and a null mutation created in particular cells or tissues ( Figure 6 ).
Two requirements need to be fulfilled for conditional gene targeting with the Cre-Lox P system: (i) a 'floxed' allele must be created in such a way that this allele is still functional; (ii) targeting of Cre expression must be tightly controlled.
Creation of 'floxed' alleles. In a pioneering work, Gu et al. (1994) devised a method to create 'floxed' alleles of a given gene. This involved the construction of a transgene, containing three Lox P sites, in the same orientation, sites 1 and 2 flanking an essential portion of the gene, and sites 2 and 3 flanking the selection cassette. Recombinant ES cells bearing the modified allele containing the three Lox P sites were then transfected with a Cre-expressing cassette, which allowed the isolation of two types of clones: one with a deleted version of the targeted allele and the other with a floxed version of the allele (see Figure 7 ). This approach was used by Gu et al. to modify the DNA polymerase β gene: mice bearing both types of modified alleles were generated and it was shown that, whereas the deleted version of the allele was lethal in the homozygous state, mice bearing two 'floxed' alleles were viable and normal. The latter mice were then used for conditional gene targeting (see below). An alternative approach is to create a 'floxed' allele by a single homologous recombination event, using a targeting vector in which two Lox P sites flank the selection marker and an essential part of the gene of interest (see for example Hennet et al., 1995; Shibata et al., 1997; Terry et al., 1997) . However, in this case, the 'floxed' alleles retain the Figure 7 ) and exhibits no phenotype (only one allele is illustrated). The second one is a transgenic mouse for a fusion transgene corresponding to the Cre recombinase coding sequence under the control of the cisacting regulatory elements of a tissue-specific promoter (here a neuronal specific gene). In the progeny, only neurons express the Cre recombinase and consequently harbour the deleted (type I, Type I contains the deletion, the phenotype of which can be assessed in vivo after transferring the mutation back into the animal. Type II corresponds to the 'floxed' allele. In-vivo deletions can be obtained by crossing mice carrying this allele with Cre-expressing transgenic mice ( Figure 6 ). The third allele can also be recovered but usually has no applications.
selection marker and particular care should be taken that the corresponding mice used in the next step for conditional gene targeting (see below) do not display a perturbation in the function and/or expression of the gene. An example where the selection marker did indeed perturb gene function was reported by Meyers et al. (1998) .
Cre-expressing mice. There are two critical points which 934 must be taken into consideration when designing a conditional targeting strategy such as the one described above: (i) expression of Cre in the transgenic mice must be tightly controlled such that it is expressed only in particular cells or tissues; (ii) Cre should be efficient enough to promote the deletion of the 'floxed' allele in all of these cells. Targeting Cre expression in vivo is achieved by creating transgenic mice bearing a fusion transgene made of promoter/regulatory sequences bound to Cre coding sequences. However, the expression of the transgene may be subject to both position effect (Wilson et al., 1990) and the combination of sequences in the fusion transgene may modify the specificity of expression. An example of such difficulties was illustrated by the study of Terry et al. (1997) in which a PECAM-1 (platelet endothelial cell adhesion molecule-1) promoter, previously shown to be active principally in endothelial cells, was used to govern Cre expression in transgenic mice. When these mice were crossed with mice bearing a 'floxed' allele of VCAM-1 (vascular adhesion molecule-1) gene, ubiquitous deletion of the latter was observed in the double transgenic mice. Similarly, Cre expression under the control of regulatory sequences of the nestin gene, previously shown to target β-galactosidase expression exclusively to the developing central nervous system, seemed to take place ubiquitously, as deletion of a 'floxed' gene in all the tissues of the double transgenic mice was observed (Betz et al., 1996) . Thus the two types of fusion transgenes promoted unexpected tissue distribution of the deleted allele, presumably for the reasons mentioned above. However, an alternative explanation for these results could be the unanticipated expression of the Cre transgene very early in development, resulting in the transmission of the deleted allele to most cells of the developing embryo. A way to control Cre expression more tightly would be to 'knock-in' the Cre by homologous recombination, thus placing the Cre sequences in the closest context of the regulatory sequences of a given gene, as exemplified by a recent study (Rickert et al., 1997) . In any event, it is essential that the pattern of Cre expression be carefully analysed prior to performing conditional gene targeting.
Examples of conditional gene targeting.
Despite the aforementioned difficulties inherent to the use of gene addition transgenic mice, the feasibility of conditional gene targeting with the Cre-Lox P system has been clearly established in several recent studies. In a first report (Gu et al., 1994) , deletion of a floxed DNA polymerase β gene, which is lethal in the homozygous state, could be specifically induced in the T-cell lineage of double transgenic mice containing the floxed gene and a fusion gene comprising the promoter/regulatory sequences of the T-cell specific lck gene linked to Cre coding sequences. Similarly, Hennet et al. (1995) described a T-cell specific deletion of the N-acetyl galactosaminyl transferase gene. A study of particular interest was that of Tsien et al. (1996a) . These authors were interested in the neuronal function of N-methyl-D-aspartate receptor 1 (NMDAR1) gene, which encodes a subunit of a postsynaptic ion channel, the inactivation of which is lethal. The authors thus set out to restrict the inactivation of this gene to a particular region of the brain. To this end, they first monitored the targeting of Cre activity, by using a reporter system made of a fusion transgene in which LacZ sequences were separated from the ubiquitously competent β-actin promoter gene by transcriptional stop sequences flanked by Lox P sites (as initially described by Lakso et al., 1992) . The corresponding transgenic mice were then crossed with other transgenic mice expressing Cre under the control of α Ca MKII (α calcium calmodulin dependent kinase II) gene promoter which is specifically active in the forebrain (Mayford et al., 1996 and references therein). Remarkably, although the pattern of β-galactosidase expression varied in the different double transgenic mice (probably due to position effects; see above), in some of them it was clearly restricted to pyramidal neurons in the CA1 region of the hippocampus, therefore indicating that functional Cre was expressed solely in these cells. Furthermore, β-galactosidase activity was developmentally regulated starting~3 weeks post-partum and present in almost 100% of the CA1 pyramidal neurons (Tsien et al., 1996a) . Cre-mediated recombination was therefore very efficient. In addition these results indicated that it can take place even in postmitotic cells such as neurons. In a subsequent study, the α Ca MKII-Cre transgenic mice were crossed with mice bearing a 'floxed' NMDAR1 gene. Analysis by in-situ hybridization of mice homozygous for the 'floxed' NMDAR1 gene and bearing the α Ca MKII-Cre transgene, showed that the deletion of the NMDAR1 gene was indeed restricted to the CA1 region of the hippocampus. These mice, in contrast to homozygous NMDAR1 KO mice which die perinatally, were viable and fertile. However, they exhibited various neurological defects including impaired spatial memory and hippocampal representation of space, therefore demonstrating the importance of NMDA receptor-mediated synaptic plasticity in the CA1 region of hippocampus (McHugh et al., 1996; Tsien et al., 1996b) .
An alternative way of obtaining restricted gene inactivation has been described more recently by Shibata et al. (1997) . These authors were interested in the study of the role of the adenomatous polyposil coli (APC) gene in familial adenomatous polyposis coli (FAP), a disease characterized by the development of multiple colorectal adenomas. Affected individuals carry germline mutations in this gene and the tumours exhibit inactivation of both alleles. Creation of an FAP mouse model had been hampered by the fact that APC deficiency induces embryonic lethality. To circumvent this problem, Shibata et al. created mice homozygous for a floxed allele obtained by homologous recombination in ES cells. These mice were viable and did not develop any tumours. To induce the deletion of the APC gene, a Cre-expressing adenovirus was injected into the colorectum of homozygous floxed APC mice. Strikingly, 80% of the mice infected with this virus developed colorectal adenomas within 4 weeks of infection, and the tumours were shown to be deprived of any functional APC protein. These experiments are a further example of the versatility of conditional targeting using the Cre-Lox P system.
Yeast I-Sce I meganuclease
A major limitation of gene targeting is the low frequency of adequate homologous recombination. Despite various improvements (increase in the length of homology, use of isogenic DNA, etc.), this remains a serious limitation. A way to circumvent this difficulty was suggested by the observation that double-strand ends of broken chromosomes are highly recombinogenic. Therefore, one could predict that induction of a double-strand break (DSB) in a specific locus should enhance the homologous recombination frequency. To address this hypothesis, Cohen-Tannoudji et al. (1998) recently devised a protocol combining the use of I-Sce I (a yeast endonuclease with an 18 bp recognition site which is therefore unlikely to be present in a mammalian genome) and the 'plug and socket' approach (Detloff et al., 1994) , a strategy facilitating repeated targeting at a single locus. In a first conventional gene targeting step, an I-Sce I recognition site was introduced in an endogenous locus together with a functional (neo) and a partial non-functional (ygro) selectable marker (Figure 8a) . In a second step, the modified ES cells were simultaneously electroporated with an I-Sce I-expressing vector and a circular replacement construct carrying an overlapping partial nonfunctional marker gene (hygr). Transiently expressed I-Sce I recognized its site, thereby creating a unique DSB at the target locus, which was efficiently repaired using the replacement construct as a repair matrix; at the same time, recombination between the two non-functional markers during the repair process reconstituted a fully functional selectable gene (hygro; Figure 8b ). Strikingly, all hygro R clones analysed appeared to have been correctly targeted; furthermore the ratio of correctly targeted clones obtained indicated a 100-fold stimulation of gene targeting frequency (Cohen-Tannoudji et al., 1998) . This result demonstrated that induction of a DSB by the use of I-Sce I dramatically enhances the efficiency of homologous recombination. This strategy should prove very useful when multiple modifications at a particular locus are desired. Indeed, the DSB repair mechanism provides two important advantages over conventional gene targeting. First the design of the targeting vectors should be facilitated, because only small regions of homology with the target locus are needed for an efficient processing. Second, any modification present in the replacement construct will be copied at the target locus upon repair, thereby opening the way to the introduction of subtle modifications in a gene of interest.
Conclusion and future prospects
Gene targeting using homologous recombination in ES cells was originally developed as a method for introducing null mutations whereby a given gene was totally inactivated. The 'knock-out' mice derived from such targeted ES cells have been invaluable in the study of gene function. In these experiments nothing but a transgene which carries a suitable length of homology with the endogenous gene as well as a selectable marker gene acting as a mutagen is introduced into ES cells. The enzymatic machinery of the ES cell performs the homologous recombination and cells bearing a null allele can usually be found after selection and screening. However, as already mentioned, KO mice have their limitations in the investigation of gene function. Thus, in recent years, methods have been developed to refine gene manipulation. Generally speaking, these methods have taken advantage of refined selection procedures and/or particular enzymatic systems initially discovered in other organisms and which have the ability to act upon the process of DNA recombination. Among these, the Cre-Lox P site-specific recombination of the bacteriophage P1 has proven extremely useful in providing a very versatile system. Indeed, it has permitted the creation of new types of mutations, such as chromosomal inversions, deletions or translocations; in addition, it has provided, besides the double replacement strategy, another way of creating 'clean mutations' i.e. devoid of foreign selectable marker sequences. Perhaps the most important virtue of the Cre-Lox P system is that it can in principle restrict gene modification to a given cell type or tissue, thereby greatly extending our ability to tackle gene function. For these kinds of experiments, the generation of a panel of Cre transgenic mice, whose pattern and level of expression is accurately assessed, will be essential.
The very recent demonstration of enhancement of homologous recombination by the creation of a double strand break at an endogenous target gene together with the fidelity of the repair process governed by an external repair matrix, should also prove valuable to facilitate gene targeting. Furthermore, combination of DSB-mediated gene targeting with other strategies like the Cre-Lox P procedure should increase the range of genetic manipulation of the mammalian genome.
Finally, an alternative and promising extension of conditional gene targeting resides in the development of systems of inducible gene expression in vivo. One of these systems was devised by Gossen et al. (1995) (reviewed in Shockett and Schatz, 1996) . These authors demonstrated that a fusion protein made of a mutated version of the tetracycline repressor sequences linked to the Herpes VP16 activating sequences (rtTA) could bind only in the presence of tetracycline to the tetracycline operator (tet O) DNA sequences, thereby promoting the activity of a LacZ or luciferase reporter gene. This result, originally obtained in cultured cells (Gossen et al., 1995) was subsequently extended to transgenic mice (Kistner et al., 1996; Mayford et al., 1996) . It should be possible to adapt this strategy to the control of Cre expression. Thus, transgenic mice could be generated, containing two transgenes, one expressing rtTA and the other consisting of tet O sequences linked to the Cre gene; depending on the specificity of the promoter used to express the fusion protein, such transgenic mice should express Cre, upon tetracycline treatment, in a given cell type at the time of treatment.
Another strategy to obtain inducible Cre expression is demonstrated by the observation that linking the ligand-binding domain of steroid receptors to a given protein results in a chimeric protein the activity of which becomes hormone dependent (Picard, 1994) . Thus, fusing recombinase with a steroid ligand-binding domain may render its activity dependent on the presence of the ligand. Indeed such a strategy was demonstrated to be operational both in cultured cells (Logie and Stewart, 1995; Metzger et al., 1995; Kellendonk et al., 1996) and in the animal: excision of a Lox P-flanked gene segment in transgenic mice expressing chimeric Cre with a mutated ligand-binding domain of the human oestrogen receptor was shown to be dependent on the administration of tamoxifen (Feil et al., 1996 (Feil et al., , 1997 . This strategy should prove instrumental for the spatiotemporal control of gene modification.
A decade ago, gene knock-out approaches opened up entirely new avenues for the analysis of mammalian gene function in vivo. However, over recent years a tremendous extension of this methodology has taken place, by affording ways of creating various kinds of mutations or even chromosomal modifications, besides gene inactivation. Furthermore, progress has been made in our ability to create gene modifications which could be restricted to a cell type or tissue, or to a given stage of development. Taken together these advances have greatly enhanced the promise of gene targeting.
